Lipid Genomics applies personalized medicine to create diagnostics and therapeutics for acute and chronic inflammatory diseases. It offers a patented LAG3 deficiency diagnostic test to identify oncology patients at higher risk of adverse events and a recombinant LAG3 biologic as a non‑antibody replacement therapy, aiming to mitigate heart disease risk linked to LAG3 deficiency.
Funding
Funding not disclosed
Founders
Product
Problem
Patients receiving LAG3‑blocking antibody therapies for cancer may have an undetected genetic deficiency in the immune checkpoint molecule LAG3, which is associated with a higher risk of cardiovascular disease and adverse treatment events. Without a means to identify this deficiency, clinicians cannot adequately assess or mitigate these risks.
Solution
Lipid Genomics offers a patented diagnostic test that detects LAG3 deficiency in oncology patients, enabling clinicians to flag individuals at elevated risk for heart disease and potential adverse reactions to LAG3‑targeted antibodies. The company also develops a recombinant LAG3 biologic that serves as a non‑antibody replacement therapy, aiming to restore LAG3 function in deficient patients. By integrating personalized medicine into both diagnostics and therapeutics, Lipid Genomics seeks to improve safety and outcomes for patients with acute and chronic inflammatory conditions, particularly those undergoing cancer immunotherapy.
Target Audience
Primary customers are oncology clinicians and healthcare providers who prescribe LAG3‑blocking antibodies, as well as pharmaceutical partners developing immune checkpoint therapies.
Features
- Patented LAG3 genetic deficiency test that identifies patients at increased cardiovascular risk and susceptibility to adverse events from LAG3‑blocking antibodies
- Clinical decision support for oncologists to tailor immunotherapy strategies based on LAG3 status
- Recombinant LAG3 biologic formulated as a non‑antibody replacement therapy to restore checkpoint function
- Proprietary technology platform linking diagnostic results to targeted therapeutic development
- Focus on acute and chronic inflammatory disease pathways beyond oncology